692 related articles for article (PubMed ID: 32124453)
21. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
22. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
23. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma.
Battula N; Reichman TW; Amiri Y; Carmody IC; Galliano G; Seal J; Bugeaud E; Bohorquez H; Bruce D; Cohen A; Loss GE
Liver Transpl; 2017 Mar; 23(3):299-304. PubMed ID: 28026108
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
25. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
[TBL] [Abstract][Full Text] [Related]
26. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
27. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
28. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
29. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
30. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
[TBL] [Abstract][Full Text] [Related]
31. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
[TBL] [Abstract][Full Text] [Related]
32. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria.
Ravaioli M; Odaldi F; Cucchetti A; Trevisani F; Piscaglia F; De Pace V; Bertuzzo VR; Neri F; Golfieri R; Cappelli A; D'Errico A; Cescon M; Del Gaudio M; Fallani G; Siniscalchi A; Morelli MC; Ciccarese F; Di Marco M; Farinati F; Giannini EG; Pinna AD
Sci Rep; 2019 Mar; 9(1):3781. PubMed ID: 30846792
[TBL] [Abstract][Full Text] [Related]
33. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
Huang AC; Dodge JL; Yao FY; Mehta N
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1581-1589. PubMed ID: 36038129
[TBL] [Abstract][Full Text] [Related]
34. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
35. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?
Ersan V; Barut B; Yilmaz S
J Gastrointest Cancer; 2020 Dec; 51(4):1152-1156. PubMed ID: 32856230
[TBL] [Abstract][Full Text] [Related]
36. What Should Be the Rules for Downstaging for Hepatocellular Carcinoma?
Dirican A; Karakas S
J Gastrointest Cancer; 2020 Dec; 51(4):1148-1151. PubMed ID: 32839945
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
[TBL] [Abstract][Full Text] [Related]
38. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
[TBL] [Abstract][Full Text] [Related]
39. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study.
Habibollahi P; Shamchi SP; Choi JM; Gade TP; Stavropoulos SW; Hunt SJ; Dagli M; Sudheendra D; Mondschein JI; Soulen MC; Nadolski GJ
J Vasc Interv Radiol; 2019 Mar; 30(3):323-329. PubMed ID: 30819472
[TBL] [Abstract][Full Text] [Related]
40. Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center.
Palmer WC; Lee D; Burns J; Croome K; Rosser B; Patel T; Keaveny AP; Pungpapong S; Satyanarayana R; Yataco M; Nakhleh R; Musto KR; Canabal AM; Turnage AK; Hodge DO; Nguyen JH; Harnois DM
Ann Hepatol; 2017; 16(3):402-411. PubMed ID: 28425410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
